ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma.

ABSTRACT: Primary liver cancer is one of the most frequently diagnosed and deadliest cancers. Zinc finger E-box binding homeobox 1 (ZEB1) is negative prognostic factor in liver cancer by promoting therapy resistance and tumorigenesis. Interfering in pathways of cellular metabolism emerges as a potent strategy to overcome tumor cells resistance to therapy. Our study aims to investigate the apoptotic potential of pharmacological inhibition of mitochondrial metabolism in primary liver cancer and whether this strategy can reduce ZEB1-associated resistance to standard of care chemotherapy Sorafenib. ZEB1 mRNA levels in patient samples and cancer cell lines were computationally screened using public datasets. Transcript and protein abundance of ZEB1 and regulators of mitochondrial fission and fusion were

SUBMITTER: Freudenstein H 

PROVIDER: S-EPMC12365315 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature